RA Capital Management | Activity | F4
RA Capital Management Activity Every public signal F4 has attached to this firm, with sources and cross-entity links.
Exit
Crinetics Therapeutics was acquired by Vertex Pharmaceuticals in July 2026. Crinetics Pharmaceuticals
Peter Kolchinsky discussed policy constraints limiting biomedical innovation in a media interview. Kolchinsky: Policy constraints holding back biomedical innovation
7 exits · NOV 2025 – JUN 2026 Show all Exit
Apogee Therapeutics was acquired by AbbVie in June 2026. Apogee Therapeutics
Exit
Portfolio company Curevo Vaccine was acquired by Eli Lilly in May 2026. Curevo Vaccine
Exit
Portfolio company Ajax Therapeutics was acquired by Eli Lilly in April 2026. Ajax Therapeutics
Exit
Portfolio company Day One Biopharmaceuticals was acquired by Servier in March 2026. Day One Biopharmaceuticals
Exit
Portfolio company Elektrofi was acquired by Halozyme Therapeutics in November 2025. Elektrofi
Exit
Portfolio company Halda Therapeutics was acquired by Johnson & Johnson in November 2025. Halda Therapeutics
Exit
Portfolio company Cidara Therapeutics was acquired by Merck & Co. in November 2025. Cidara Therapeutics
Investment
Provided up to $250M structured loan facility ($100M initial) to ARS Pharma alongside OMERS Life Sciences to fund commercialization of neffy needle-free epinephrine nasal spray. ARS Pharmaceuticals
4 exits · AUG 2025 – SEP 2025 Show all Exit
Portfolio company 89bio was acquired by Roche in September 2025. 89bio
Exit
Portfolio company Metsera was acquired by Pfizer in September 2025. Metsera
Exit
Portfolio company Merus was acquired by Genmab in September 2025. Merus
Exit
Portfolio company HilleVax was acquired by Xoma Royalty in August 2025. HilleVax